Filana Therapeutics is a pre-revenue neurology biotechnology company whose entire equity narrative now turns on a single asset, simufilam, a first-in-class filamin A modulator being developed for tuberous sclerosis complex, or TSC, related epilepsy. The fundamental change underway is a regulatory one. A formal full clinical hold from the U.S. Food and Drug Administration, dated December 15, 2025, sits on the proof-of-concept IND for the TSC program, and the company is working through the requested preclinical and protocol items.
The underlying economics are modest and cash-constrained. The net loss for the three months ended June 30, 2026 was $8.6 million, or $0.18 per share, and the accumulated deficit stood at $515.0 million. At a $0.96 close, the roughly 48 million shares outstanding produce a market capitalization near $46 million, inside a 52-week range of $0.85 to $4.98.
The quarter's evidence is the $8.6 million burn against a $46 million equity value, a ratio that leaves the balance sheet thin relative to the cost of resolving a clinical hold. Whether FDA lifts the hold on simufilam's TSC program before the existing cash is consumed is the question that decides whether this stock has a future.